Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis

Mattthew James Sinclair Parker,Adelle S Jee,Dylan Hansen,Susanna Proudman,Peter Youssef,Tony J Kenna,Wendy Stevens,Mandana Nikpour,Joanne Sahhar,Tamera J Corte

DOI: https://doi.org/10.1093/rheumatology/keae110

2024-02-15

Rheumatology

Abstract:Abstract Objectives To investigate the prognostic utility of 28 serum biomarkers in systemic sclerosis (SSc), SSc-associated interstitial lung disease (SSc-ILD) and clinically relevant disease subgroups Methods Participants with sera, high-resolution computed tomography, and lung function within 12 months of baseline were identified from the Australian Scleroderma Cohort Study. Baseline was the time of serum collection. 27 of the prespecified 28 serum biomarkers were analysed and biomarker associations with mortality and ILD progression were investigated in univariable and multivariable analyses, including within disease subgroups and combined with established risk factors for poorer prognosis in SSc. Results 407 participants were identified, 252 (61.9%) with SSc-ILD. The median follow up after biomarker measurement was 6.31 (3.11–9.22) years. 16 biomarkers were associated with increased mortality. High levels of VCAM-1 were most strongly associated with mortality (HR 3.55; 95%CI 2.37–5.33; p< 0.001). Five additional biomarkers had a HR > 2: SP-D (2.28, 1.57–3.31; p< 0.001), E-selectin (2.19; 1.53–3.14; p< 0.001), IL-6 (2.15 1.50–3.09; p< 0.001), MMP3 (1.42–2.95; p< 0.001) and ET-1 (2.03, 1.40–2.92; p< 0.001). 11 biomarkers were independently associated with mortality following adjustment for sex, age and baseline forced vital capacity (FVC%predicted). Three biomarkers were associated with ILD progression at one year follow up: CXCL4 (OR 2.67, 1.46–4.88; p= 0.001), MMP-1 (2.56, 1.43–4.59; p= 0.002) and ET-1 (2.18, 1.24–3.83; p= 0.007). Conclusion Multiple biomarkers, especially VCAM-1, E-Selectin, SP-D and CXCL4, provide prognostic utility beyond that of established risk factors for patients with SSc.

rheumatology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the prognostic value of 28 serum biomarkers in predicting patient mortality and the progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) and its related SSc - ILD by detecting these biomarkers. Specifically, the study aims to: 1. **Evaluate the prognostic utility of 28 serum biomarkers**: Whether these biomarkers can be used independently or in combination with known risk factors (such as gender, age, and the predicted percentage of forced vital capacity at baseline, FVC%) to predict the mortality of SSc patients and the progression of ILD. 2. **Identify biomarker associations in specific disease subgroups**: In different subgroups (such as early - stage disease, diffuse and limited - type diseases, limited and extensive ILD, and the presence or absence of pulmonary arterial hypertension, PAH), which biomarkers are associated with mortality and the progression of ILD. ### Main findings - **Strong association between VCAM - 1 and mortality**: Regardless of whether ILD is present or not, high VCAM - 1 levels are significantly associated with higher mortality. In multivariate analysis, even after adjusting for gender, age, and baseline FVC%, VCAM - 1 remains the strongest predictor of mortality. - **Other important biomarkers**: - **E - selectin**: It is associated with mortality in almost all subgroups. - **SP - D**: It is associated with mortality, especially in patients who have already developed major internal organ manifestations. - **CXCL4**: It is associated with ILD progression in univariate analysis and also shows certain prognostic value in multivariate analysis. - **ET - 1**: It is particularly associated with mortality in patients with early - stage and limited - type diseases. - **CXCL12**: It has a particularly strong association with mortality in patients without ILD. ### Conclusions - Multiple serum biomarkers, especially VCAM - 1, E - selectin, SP - D, and CXCL4, provide prognostic value beyond known risk factors and are helpful for more accurately predicting the prognosis of SSc patients. - The discovery of these biomarkers may be helpful for guiding clinical management and treatment decisions, especially in the early identification of high - risk patients. ### Formulas - **Hazard Ratio (HR)**: Used to describe the relationship between biomarkers and mortality. For example, the relationship between VCAM - 1 and mortality is \( \text{HR} = 3.55 \) (95% CI 2.37–5.33; P < 0.001). - **Odds Ratio (OR)**: Used to describe the relationship between biomarkers and ILD progression. For example, the relationship between CXCL4 and ILD progression is \( \text{OR} = 2.67 \) (95% CI 1.46–4.88; P = 0.001). These findings provide new tools for the prognostic assessment of SSc patients and are helpful for better managing this complex disease.

Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis

Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis

Predictors of progression in systemic sclerosis patients with interstitial lung disease

KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD)

Early and accurate diagnosis of systemic sclerosis-related interstitial lung disease: matrix metalloproteinases and their inhibitors as promising biomarkers

High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies

Serum IL-17 and TNFα as prognostic biomarkers in systemic sclerosis patients: a prospective study

Serum levels of vascular dysfunction markers reflect disease severity and stage in systemic sclerosis patients

The soluble receptor for advanced glycation end products is potentially predictive of pulmonary arterial hypertension in systemic sclerosis

Proteomic Biomarkers of Progressive Fibrosing Interstitial Lung Disease: a Multicentre Cohort Analysis.

Serum CCL24 as a biomarker of fibrotic and vascular disease severity in Systemic Sclerosis

IL-13 and IL-33 Serum Levels Are Increased in Systemic Sclerosis Patients With Interstitial Lung Disease

Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease

Development of a multivariable prediction model for progression of systemic sclerosis-associated interstitial lung disease

Diagnostic performance of specific biomarkers for interstitial lung disease: a single center study

Surfactant Protein D is Associated with 3-Month Mortality of Anti-Mda5 Antibody-Interstitial Lung Disease

Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trial

Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis

Predictive factors for interstitial lung disease progression in a Singapore systemic sclerosis cohort: a multicentre study

P134 Developing a potential composite pharmacodynamic serum marker of skin severity in systemic sclerosis

Serum cold-inducible RNA-binding protein levels as a potential biomarker for systemic sclerosis-associated interstitial lung disease